Coronary Artery Disease (CAD) Clinical Trial
Official title:
Prognostic Value of High Dose Dobutamine Stress Magnetic Resonance in Patients With Ischemic Heart Disease. Assessment of Myocardial Perfusion and Wall Motion.
High-dose dobutamine/atropine stress cardiac magnetic resonance imaging (DS-MRI) has been
incorporated in daily clinical practice for the detection of ischemic heart disease.
Thus, wall motion abnormalities (WMA) during stress, precede the development of ST-segment
depression on ECG and of anginal symptoms and aid in the detection of anatomically
significant coronary artery disease (CAD).
DS-MRI offers the possibility to integrate myocardial perfusion and wall motion analysis in
a single examination. In this regard, recent data suggest that the assessment of myocardial
wall motion and perfusion during a single session may enhance the sensitivity of the
technique for the diagnosis of CAD.
However, to date limited data is available on the prognostic value of high-dose DS-MRI in
large patient cohorts, treated according to current guidelines.
Assessment of long-term outcome of DS-MRI is important because this test may identify both
high-risk patients, who would benefit from invasive diagnostic and therapy, and lower-risk
patients in whom additional procedures and intensive medical follow-up are not required.
In the present study we aim to determine the value of wall motion and perfusion assessment
during high-dose dobutamine/atropine MRI in predicting cardiac events.
In addition, the incremental value of the MR-stress testing results was assessed (inducible
wall motion, perfusion abnormalities and the combination of both) after the consideration of
traditional clinical risk factors and baseline ejection fraction.
Background: High-dose dobutamine stress cardiac magnetic resonance imaging (DS-MRI) is
incorporated in daily clinical practice for the detection of coronary artery disease (CAD).
Purpose: To determine the value of wall motion and perfusion assessment during DS-MRI for
the prediction of cardiac events in a large patient cohort.
Methods:
Cardiovascular MR-Examination. Patients are examined in a clinical 1.5-T whole-body
MR-scanner Achieva system (Philips Medical Systems, Best, The Netherlands) using a 5-element
cardiac phased-array receiver coil. Cardiovascular MR-images were acquired at rest and
during a standardized high-dose dobutamine/atropine protocol involving short breath holds,
and using a vector electrocardiogram for R-wave triggering11. Electrocardiographic rhythm
and symptoms were monitored continuously, and blood pressure was measured every 3 minutes.
Follow-up Data. Personnel unaware of the stress testing results contacts each subject or an
immediate family member and the date of this contact was used for calculating the follow-up
time duration. Outcome data iscollected from a standardized questionnaire and determined
from patient interviews at the outpatient clinic or by telephone interviews. Reported
clinical events are confirmed by review of the corresponding medical records in our
electronic Hospital Information System (HIS), contact with the general practitioner,
referring cardiologist or the treating hospital. Cardiac death and nonfatal myocardial
infarction are registered as major cardiac events. Cardiac death is defined as death from
any cardiac cause (lethal arrhythmia, myocardial infarction, or congestive heart failure) or
sudden unexpected death occurring without another explanation. Myocardial infarction is
defined by angina of >30 minutes duration and either ST segment elevation of ≥2mm in 2
consecutive ECG leads or a rise in troponin T of ≥0.03µg/l.
Other events include clinically indicated coronary arterial revascularization by
percutaneous coronary angioplasty (PCI) or coronary artery bypass graft (CABG).
In case of 2 simultaneous cardiac events, the worst event was selected (cardiac
death>non-fatal myocardial infarction>revascularization).
;
Observational Model: Cohort, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05292079 -
CAPTURER PMCF Study ( rEPIC04D )
|
||
Recruiting |
NCT05292118 -
Navitian PMCF Study ( rEPIC04C )
|
||
Recruiting |
NCT05292092 -
Essential Pro PMCF Study ( rEPIC04E )
|
||
Recruiting |
NCT05292014 -
ANGIOLITE PMCF Study ( rEPIC04F )
|
||
Completed |
NCT05292105 -
NC Xperience PMCF Study( rEPIC04B)
|
||
Terminated |
NCT01443754 -
Hybrid Revascularisation by Combined Coronary Artery Bypass Graft (CABG) and PCI in Multivessel Coronary Disease
|
N/A | |
Completed |
NCT01435031 -
EXPERT CTO: Evaluation of the XIENCE PRIME™ LL and XIENCE Nano™ Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions
|
N/A | |
Completed |
NCT00783302 -
Study in Subjects Suspected of Having CAD Undergoing VISIPAQUE-enhanced CCTA as Part of Their Routine Medical Care
|
N/A | |
Completed |
NCT00543400 -
Evaluation of M118 in Percutaneous Coronary Intervention (EMINENCE)
|
Phase 2 | |
Completed |
NCT05516784 -
Impact of CYP2C19 Genotype-guided Clopidogrel and Ticagrelor Treatment on Platelet Function Test and Metabolomics Profile
|
Phase 4 | |
Completed |
NCT02873052 -
MyoVista Measurements in Patients With Atherosclerosis and CAD
|
||
Terminated |
NCT02984891 -
Optical Coherence Tomography (OCT) Intravascular Ultrasound (IVUS) Dual Imaging
|
||
Completed |
NCT05292144 -
Xperience Pro PMCF Study
|
||
Completed |
NCT02554292 -
Post Market Surveillance of SeQuent Please Neo With Scoring Balloon
|
||
Active, not recruiting |
NCT06052319 -
A Study to Assess the Engagement and Usefulness of Care4Today Digital Platform for Disease Management in Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD) Population
|
||
Completed |
NCT00265525 -
Evaluation of a Web-based Intervention to Promote Physical Activity in Patients With Heart Disease.
|
Phase 3 | |
Completed |
NCT03570697 -
Imaging of Coronary Plaques in Participants Treated With Evolocumab
|
Phase 3 | |
Terminated |
NCT05508893 -
Screening for Coronary Artery Disease USing Primary Evaluation With Coronary CTA in Aviation Medicine (SUSPECT)
|
N/A | |
Completed |
NCT02341664 -
Patient and Provider Assessment of Lipid Management Registry
|
||
Completed |
NCT02098772 -
Phase III Study Comparing Two Methods of Cardioplegia in Aortic Valve Surgery Custodiol-N Versus Custodiol
|
Phase 3 |